中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Value of different scoring models in predicting the survival of patients with liver cirrhosis after transjugular intrahepatic portosystemic shunt

DOI: 10.3969/j.issn.1001-5256.2023.03.016
Research funding:

National Natural Science Foundation of China (82170594)

More Information
  • Corresponding author: CHEN Dongfeng, chendf1981@126.com (ORCID: 0000-0001-5514-7358)
  • Received Date: 2022-11-10
  • Accepted Date: 2022-12-29
  • Published Date: 2023-03-20
  •   Objective  To compare the value of Child-Pugh score, Model for End-Stage Liver Disease (MELD) score, MELD combined with serum sodium concentration (MELD-Na) score, CLIF Consortium Acute Decompensation (CLIF-C AD) score, and Freiburg index of post-transjugular intrahepatic portosystemic shunt (TIPS) survival (FIPS) score in predicting the survival of patients undergoing TIPS.  Methods  A retrospective analysis was performed for the clinical data of 447 patients with liver cirrhosis who underwent TIPS in several hospitals in southwest China, among whom there were 306 patients in the survival group and 62 in the death group. The scores of the above five models were calculated, and a survival analysis was performed based on these models. The independent samples t-test was used for comparison of normally distributed continuous data between groups, and the non-parametric Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the Pearson chi-square test was used for comparison of categorical data between groups; a multivariate Cox regression analysis was used for correction analysis of known influencing factors with statistical significance which were not included in the scoring models; the Kaplan-Meier method was used to evaluate the discriminatory ability of each model in identifying risks in the surgical population, and the log-rank test was used for analysis. The area under the receiver operating characteristic curve (AUC), C-index at different time points, and calibration curve were used to evaluate the predictive ability of each scoring model.  Results  Compared with the death group, the survival group had significantly lower age (Z=2.884, P < 0.05), higher albumin (t=3.577, P < 0.05), and Na+ (Z=-3.756, P < 0.05) and significantly lower proportion of patients with alcoholic cirrhosis (χ2=22.674, P < 0.05), aspartate aminotransferase (Z=2.141, P < 0.05), prothrombin time (Z=2.486, P < 0.05), international normalized ratio (Z=2.429, P < 0.05), total bilirubin (Z=3.754, P < 0.05), severity of ascites (χ2=14.186, P < 0.05), and scores of the five models (all P < 0.05). Survival analysis showed that all scoring models effectively stratified the prognostic risk of the patients undergoing TIPS. Comparison of the C-index of each scoring model at different time points showed that Child-Pugh score had the strongest ability in predicting postoperative survival, followed by MELD-Na score, MELD score, and CLIF-C AD score, and FIPS score had a relatively poor predictive ability; in addition, the prediction efficiency of each score gradually decreased over time. Child-Pugh score had the largest AUC of 0.832 in predicting 1-year survival rate after surgery, and MELD-Na score had the largest AUC of 0.726 in predicting 3-year survival rate after surgery, but FIPS score had a poor ability in predicting 1- and 3-year survival rates.  Conclusion  All five scoring models can predict the survival of patients with liver cirrhosis after TIPS and can provide effective stratification of prognostic risk for such patients. Child-Pugh score has a better ability in predicting short-term survival, while MELD-Na score has a better ability in predicting long-term survival, but FIPS score has a relatively poor predictive ability in predicting both short-term and long-term survival.

     

  • [1]
    BOIKE JR, THORNBURG BG, ASRANI SK, et al. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1636-1662.e36. DOI: 10.1016/j.cgh.2021.07.018.
    [2]
    Chinese College of Interventionalists. CCI clinical practice guidelines: management of TIPS for portal hypertension (2019 edition)[J]. J Clin Hepatol, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.

    中国医师协会介入医师分会. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2694-2699. DOI: 10.3969/j.issn.1001-5256.2019.12.010.
    [3]
    LIU F, ZHAO JB, WANG JY, et al. Transjugular intrahepatic portosystemic shunt via jugular vein by using specialized covered stent: 2-year follow-up observation[J]. J Interv Radiol, 2021, 30: 888-892. DOI: 10.3969/j.issn.1008-794X.2021.09.007.
    [4]
    PUGH RN, MURRAY-LYON IM, DAWSON JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973, 60: 646-649. DOI: 10.1002/bjs.1800600817.
    [5]
    MALINCHOC M, KAMATH PS, GORDON FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31(4): 864-871. DOI: 10.1053/he.2000.5852.
    [6]
    BIGGINS SW, KIM WR, TERRAULT NA, et al. Evidence-based incorporation of serum sodium concentration into MELD[J]. Gastroenterology, 2006, 130(6): 1652-1660. DOI: 10.1053/j.gastro.2006.02.010.
    [7]
    JALAN R, PAVESI M, SALIBA F, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure[J]. J Hepatol, 2015, 62(4): 831-840. DOI: 10.1016/j.jhep.2014.11.012.
    [8]
    BETTINGER D, STURM L, PFAFF L, et al. Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival[J]. J Hepatol, 2021, 74(6): 1362-1372. DOI: 10.1016/j.jhep.2021.01.023.
    [9]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
    [10]
    COLAPINTO RF, STRONELL RD, BIRCH SJ, et al. Creation of an intrahepatic portosystemic shunt with a Grüntzig balloon catheter[J]. Can Med Assoc J, 1982, 126(3): 267-268.
    [11]
    GIANNINI E, BOTTA F, FUMAGALLI A, et al. Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients?[J]. Liver Int, 2004, 24(5): 465-470. DOI: 10.1111/j.1478-3231.2004.0949.x.
    [12]
    HUO TI, WANG YW, YANG YY, et al. Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis[J]. Liver Int, 2007, 27(4): 498-506. DOI: 10.1111/j.1478-3231.2007.01445.x.
    [13]
    RUBIN RA, HASKAL ZJ, O'BRIEN CB, et al. Transjugular intrahepatic portosystemic shunting: decreased survival for patients with high APACHE Ⅱ scores[J]. Am J Gastroenterol, 1995, 90(4): 556-563.
    [14]
    PARVINIAN A, SHAH KD, COUTURE PM, et al. Older patient age may predict early mortality after transjugular intrahepatic portosystemic shunt creation in individuals at intermediate risk[J]. J Vasc Interv Radiol, 2013, 24(7): 941-946. DOI: 10.1016/j.jvir.2013.03.018.
    [15]
    FENG IC, TZENG WS, WANG SJ, et al. The role of transjugular intrahepatic portosystemic shunt in acute variceal bleeding: differential survival owing to different cirrhosis etiology[J]. J Gastroenterol, 2010, 27: 166-174. DOI: 10.6557/GJT.201006_27(2)0.0001
    [16]
    SAAD N, RUDE MK, DARCY M, et al. Older age is associated with increased early mortality after transjugular intrahepatic portosystemic shunt[J]. Ann Hepatol, 2016, 15(2): 215-221. DOI: 10.5604/16652681.1193716.
    [17]
    LI J, TANG S, ZHAO J, et al. Long-term survival prediction for transjugular intrahepatic portosystemic shunt in severe cirrhotic ascites: assessment of ten prognostic models[J]. Eur J Gastroenterol Hepatol, 2021, 33(12): 1547-1555. DOI: 10.1097/MEG.0000000000001890.
    [18]
    ASCHA M, ABUQAYYAS S, HANOUNEH I, et al. Predictors of mortality after transjugular portosystemic shunt[J]. World J Hepatol, 2016, 8(11): 520-529. DOI: 10.4254/wjh.v8.i11.520.
    [19]
    WEN L, HE S, ZHANG H, LUO X. Comparison study of five scoring systems for evaluating prognosis of patients undergoing transjugular intrahepatic portosystemic shunt procedures[J]. Chin J Hepatol, 2014, 22: 514-518. DOI: 10.3760/cma.j.issn.1007-3418.2014.07.008.

    文龙跃, 何松, 张浩, 等. 五种评分系统对经颈静脉肝内门体静脉分流术患者预后的评价比较[J]. 中华肝脏病杂志, 2014, 22: 514-518. DOI: 10.3760/cma.j.issn.1007-3418.2014.07.008.
    [20]
    SCHEPKE M, ROTH F, FIMMERS R, et al. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting[J]. Am J Gastroenterol, 2003, 98(5): 1167-1174. DOI: 10.1111/j.1572-0241.2003.07515.x.
    [21]
    ANGERMAYR B, CEJNA M, KARNEL F, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt[J]. Gut, 2003, 52(6): 879-885. DOI: 10.1136/gut.52.6.879.
    [22]
    YANG C, CHEN Q, ZHOU C, et al. FIPS score for prediction of survival after TIPS placement: External validation and comparison with traditional risk scores in a cohort of chinese patients with cirrhosis[J]. AJR Am J Roentgenol, 2022, 219(2): 255-267. DOI: 10.2214/AJR.21.27301.
    [23]
    LV Y, WANG Z, LI K, et al. Risk stratification based on chronic liver failure consortium acute decompensation score in patients with child-pugh B cirrhosis and acute variceal bleeding[J]. Hepatology, 2021, 73(4): 1478-1493. DOI: 10.1002/hep.31478.
  • Relative Articles

    [1]Li Na, Gou Wei, Cui WeiLi. Efficacy of telbivudine combined with adefovir dipivoxil and pegylated interferon combined with entecavir as antiviral therapy for chronic hepatitis B: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(9): 1714-1716. doi: 10.3969/j.issn.1001-5256.2016.09.015
    [2]Yang DongQiang, Chen Fang, Kang Yi, Ding GangQiang, Xiao ErHui, Peng Zhen, Shang Jia. Genotypes and resistance loci in patients with chronic hepatitis B achieving virologic breakthrough in treatment with lamivudine combined with adefovir after developing drug resistance in treatment with lamivudine alone[J]. Journal of Clinical Hepatology, 2016, 32(3): 480-483. doi: 10.3969/j.issn.1001-5256.2016.03.016
    [3]Zhang Wen, Yu JianGuo, Zhu GuiZhong, Zhao ZhanDong, Wang XiaoWei. Clinical efficacy of entecavir combined with adefovir in chronic hepatitis B patients with high viral load[J]. Journal of Clinical Hepatology, 2014, 30(11): 1169-1172. doi: 10.3969/j.issn.1001-5256.2014.11.019
    [4]Huang MeiJin, Tan HouJi, He YanZhuan, Huang QiWen, Zhou YaoNan, Qiu HaiXian. Forty-eight-week efficacy of adefovir dipivoxil alone versus combined with lamivudine in treatment of lamivudine-resistant HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(7): 636-638. doi: 10.3969/j.issn.1001-5256.2014.07.015
    [5]Ruan BingWei, Lu XiaoJu, Lin YanMing, Chen RongCe, Chen XinZhi, Ceng GuangZhong, Liu YanPing. Evaluation of adverse reactions induced by adefovir dipivoxil in 85 chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2013, 29(2): 104-106.
    [6]Ma YanHong. Clinical effect of initial combination therapy with lamivudine plus adefovir dipivoxil in 48-week treatment of HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(8): 631-632. doi: 10.3969/j.issn.1001-5256.2013.08.020
    [7]Yan HaiMing, Chen JianHua, Ye YiNong, Long Hui, Wang XiangHuai. Clinical effects of lamivudine combined with adefovir dipivoxil and entecavir alone in 48-week treatment of HBeAg-positive chronic hepatitis B:preliminary comparative study[J]. Journal of Clinical Hepatology, 2013, 29(7): 508-511. doi: 1001-5256 (2013) 07-0508-04
    [8]Song MinNing, Huang WenQi, Min Feng, Hong MeiZhu, Fan RongHua, Wu WeiBing, Zhang Li. The efficacy of 3 years adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance[J]. Journal of Clinical Hepatology, 2012, 28(1): 29-32.
    [9]Liu LongGen, Ye ChunYan, Tong XueCheng. Maintenance of negative HBV DNA in patients with chronic hepatitis B during 96 weeks followup with active replacement of Adefovir dipivoxil with Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(3): 292-294.
    [10]Geng JianZhang, Fan XiaoHong, Lu HaiYing, Li Jing, Tian XiuLan, Xu XiaoYuan. The evaluation of de novo combination of antiviral treatment to hepatitis B patients with decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(8): 837-839+843.
    [11]Gu QiangYe, Li Qin, Ge XiuLin. Observation of long-term efficacy of different treatment protocol of Adefovir dipivoxil in chronic hepatitis B patients with Lamivudine-resistance[J]. Journal of Clinical Hepatology, 2011, 27(4): 411-413.
    [12]Song MinNing, Zhang Li, Huang WenQi, Min Feng. Treatment of chronic hepatitis B with Adefovir dipivoxil:A 3 years observation of clinical efficacy and drug resistance[J]. Journal of Clinical Hepatology, 2010, 26(1): 22-24.
    [13]Yang YaFang, Yang XiaoPing, Dong JianGuo, Wang ZhiGang, Liu YanPing, Zhao TieJun, Gao Feng.

    Analysis of short-term efficacy of entecavir and adefovir dipivoxil in the treatment of HBeAg-positive chronic hepatitis B

    [J]. Journal of Clinical Hepatology, 2010, 26(3): 326-327.
    [14]Zhu FeiYan. The clinical effect Adefovir dipivoxil in Lamivudine resistant HBeAg positive chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2010, 26(5): 517-518.
    [19]Cao TianGao, Li JingNan, Shi YunZhen, Li ChaoXia. The clinical study of foscarnet sodium combined with adefovir dipivoxil for lamivudine-resistant patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(4): 248-250.
  • Cited by

    Periodical cited type(11)

    1. 肖春桃,李贤秋,甘佩灵,潘潇,周贤. 基于倾向性评分匹配分析门静脉血栓对肝硬化患者预后的影响. 临床肝胆病杂志. 2021(08): 1829-1835 . 本站查看
    2. 王彤,牛焕章,杜廷伟,魏乐群. 乙型肝炎肝硬化患者门静脉血栓发生的影响因素及抗凝治疗效果研究. 深圳中西医结合杂志. 2021(17): 134-136 .
    3. 姜炅,袁佳,史海涛,戴社教. 血清ALT、AST联合NFS评分对非酒精性脂肪性肝硬化患者食管胃底静脉曲张严重程度的评估价值. 中西医结合肝病杂志. 2020(04): 314-317 .
    4. 李英,高磊,胡扬喜,胡德升. 低分子肝素钙联合右旋糖酐在肝硬化门静脉高压症术后静脉血栓形成预防中的应用. 肝脏. 2019(07): 788-790 .
    5. 吕靖,董思思,顾宏图,赵长青,刘成海. 肝硬化并发门静脉血栓的危险因素及中医证候特点. 临床肝胆病杂志. 2019(10): 2210-2213 . 本站查看
    6. 陈仙艳. 肝硬化合并上消化道出血患者门静脉血栓形成危险因素分析与护理. 护理实践与研究. 2019(18): 13-15 .
    7. 牟思玉,杨哲,吴力群,邱轩,郭珈铭. 肝硬化门静脉高压脾切除术后门静脉血栓形成的预测因素分析. 临床肝胆病杂志. 2018(01): 106-111 . 本站查看
    8. 张津瑜,陈文显,沈华,王雁,张国雷,慎华平,吴万波,魏云海. 大鼠门静脉系统血栓形成模型的建立和观察. 中国普通外科杂志. 2018(06): 724-731 .
    9. 邢文立,李谦. 重症监护病房肝病患者的血栓预防与出血控制. 临床肝胆病杂志. 2018(10): 2237-2240 . 本站查看
    10. 李志州,向俊峰,周威,唐亮. 探讨门脉高压及外伤性脾破裂行脾切除术后血小板升高及门静脉血栓形成情况. 肝胆外科杂志. 2018(04): 280-282 .
    11. 王士浩,张宏伟. 肝硬化合并门静脉血栓形成危险因素的病例对照研究. 中国中西医结合消化杂志. 2017(11): 867-870 .

    Other cited types(12)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 15.1 %FULLTEXT: 15.1 %META: 80.5 %META: 80.5 %PDF: 4.4 %PDF: 4.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.7 %其他: 4.7 %其他: 0.6 %其他: 0.6 %Bengaluru: 0.2 %Bengaluru: 0.2 %China: 0.7 %China: 0.7 %India: 0.2 %India: 0.2 %Japan: 0.1 %Japan: 0.1 %Kennedy Town: 0.2 %Kennedy Town: 0.2 %North Point: 0.2 %North Point: 0.2 %Seattle: 0.1 %Seattle: 0.1 %United States: 0.2 %United States: 0.2 %[]: 0.4 %[]: 0.4 %上海: 9.5 %上海: 9.5 %东莞: 0.6 %东莞: 0.6 %中卫: 0.1 %中卫: 0.1 %佛山: 0.2 %佛山: 0.2 %佳木斯: 0.1 %佳木斯: 0.1 %北京: 9.3 %北京: 9.3 %南京: 0.6 %南京: 0.6 %南宁: 0.1 %南宁: 0.1 %南阳: 0.1 %南阳: 0.1 %印度泰米尔纳德: 0.1 %印度泰米尔纳德: 0.1 %厦门: 0.1 %厦门: 0.1 %台北: 0.1 %台北: 0.1 %台州: 0.1 %台州: 0.1 %合肥: 0.3 %合肥: 0.3 %周口: 0.1 %周口: 0.1 %哈尔滨: 0.1 %哈尔滨: 0.1 %唐山: 0.1 %唐山: 0.1 %喀什: 0.2 %喀什: 0.2 %圣地亚哥: 0.1 %圣地亚哥: 0.1 %大连: 0.4 %大连: 0.4 %天津: 0.4 %天津: 0.4 %常德: 0.1 %常德: 0.1 %广州: 1.0 %广州: 1.0 %张家口: 1.4 %张家口: 1.4 %成都: 0.2 %成都: 0.2 %扬州: 0.3 %扬州: 0.3 %无锡: 0.2 %无锡: 0.2 %晋城: 0.2 %晋城: 0.2 %杭州: 0.5 %杭州: 0.5 %柳州: 0.1 %柳州: 0.1 %武汉: 0.3 %武汉: 0.3 %水牛城: 0.1 %水牛城: 0.1 %永州: 0.2 %永州: 0.2 %沈阳: 0.2 %沈阳: 0.2 %沈阳市和平区: 0.1 %沈阳市和平区: 0.1 %泰安: 0.2 %泰安: 0.2 %泰州: 0.3 %泰州: 0.3 %洛阳: 0.4 %洛阳: 0.4 %济南: 0.6 %济南: 0.6 %海得拉巴: 0.1 %海得拉巴: 0.1 %深圳: 0.5 %深圳: 0.5 %渭南: 0.1 %渭南: 0.1 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.1 %漯河: 0.1 %百色: 0.2 %百色: 0.2 %眉山: 0.1 %眉山: 0.1 %石嘴山: 0.1 %石嘴山: 0.1 %石家庄: 0.1 %石家庄: 0.1 %秦皇岛: 0.2 %秦皇岛: 0.2 %米兰: 0.1 %米兰: 0.1 %美国伊利诺斯芝加哥: 0.1 %美国伊利诺斯芝加哥: 0.1 %聊城市东昌府区: 0.1 %聊城市东昌府区: 0.1 %芒廷维尤: 38.2 %芒廷维尤: 38.2 %芝加哥: 0.3 %芝加哥: 0.3 %苏州: 0.1 %苏州: 0.1 %莫斯科: 0.6 %莫斯科: 0.6 %莱芜: 0.1 %莱芜: 0.1 %菏泽: 0.2 %菏泽: 0.2 %萍乡: 0.1 %萍乡: 0.1 %葵涌: 0.1 %葵涌: 0.1 %衢州: 0.1 %衢州: 0.1 %西宁: 14.2 %西宁: 14.2 %西安: 2.2 %西安: 2.2 %西安市新城区: 0.1 %西安市新城区: 0.1 %许昌: 0.1 %许昌: 0.1 %诺沃克: 0.1 %诺沃克: 0.1 %贵阳: 0.1 %贵阳: 0.1 %赤峰: 0.1 %赤峰: 0.1 %运城: 1.0 %运城: 1.0 %郑州: 0.2 %郑州: 0.2 %重庆: 0.1 %重庆: 0.1 %长春: 0.6 %长春: 0.6 %长沙: 2.2 %长沙: 2.2 %长治: 0.1 %长治: 0.1 %雅安: 1.0 %雅安: 1.0 %青岛: 0.4 %青岛: 0.4 %香港: 0.2 %香港: 0.2 %驻马店: 0.1 %驻马店: 0.1 %黄冈: 0.2 %黄冈: 0.2 %其他其他BengaluruChinaIndiaJapanKennedy TownNorth PointSeattleUnited States[]上海东莞中卫佛山佳木斯北京南京南宁南阳印度泰米尔纳德厦门台北台州合肥周口哈尔滨唐山喀什圣地亚哥大连天津常德广州张家口成都扬州无锡晋城杭州柳州武汉水牛城永州沈阳沈阳市和平区泰安泰州洛阳济南海得拉巴深圳渭南湘潭漯河百色眉山石嘴山石家庄秦皇岛米兰美国伊利诺斯芝加哥聊城市东昌府区芒廷维尤芝加哥苏州莫斯科莱芜菏泽萍乡葵涌衢州西宁西安西安市新城区许昌诺沃克贵阳赤峰运城郑州重庆长春长沙长治雅安青岛香港驻马店黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(2)

    Article Metrics

    Article views (518) PDF downloads(117) Cited by(23)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return